EP Patent

EP2655374B1 — N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors

Assigned to Incyte Holdings Corp · Expires 2019-10-23 · 7y expired

What this patent protects

Patent listed against ruxolitinib-phosphate.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: EP2655374B1
Jurisdiction: EP
Classification: —
Expires: 2019-10-23
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Holdings Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.